Navigation Links
Hadasit Bio-Holdings CEO Letter to Shareholders
Date:4/9/2013

s conditionally based on initially investing a relatively small amount of capital in order to finance a feasibility trial with one of Hadassah's specialists, while having the option of investing significantly after the initial trial if successful. We are also looking into the possibility of diversifying our portfolio by adding companies that develop  products which require less regulation and present a shorter time to market, such as medical devices and medical IT – fields in which Hadassah is already an established world leader.

In summary, we feel that our maturing portfolio, unique list of valuable assets, proven expertise in numerous fields of science, and experienced and hands-on management, coupled with an attractive share price and substantial growth potential for the Israeli biotechnology industry – all make HBL a highly attractive investment opportunity. Furthermore, the fact that an investment in the Company would directly help progress the research and development of innovative medical treatments with the potential to save thousands or even millions of lives from all over the world make it not only rewarding financially, but important in many other ways.

We remain confident in our assertion that 2013 promises to be a noteworthy year for HBL and its investors. We are immensely proud to have your confidence as shareholders, potential investors and partners for success. Your continued support and involvement only validates and affirms our corporate mission; to not only be a success financially, but to succeed in providing innovative medical treatments for the betterment of mankind.

About Hadasit Bio-Holdings

Hadasit Bio-Holdings, Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercial
'/>"/>

SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
3. Hadasit Bio-Holdings Interviewed by Wall Street Reporter
4. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
5. NeoStems CEO Letter to Shareholders
6. Genesis Biopharma Issues Letter To Shareholders
7. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
9. Ronald L. Chez Files Amended 13D and Letter to the Board
10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
11. Amarantus BioSciences Issues CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm ... quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC International ... “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on ...
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... palm plantations will worsen the dual environmental crises of ... protected, warn scientists in the most comprehensive review of ... from the Zoological Society of London and University of ... the role of palm oil production in tropical deforestation ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... board of directors appointed Dr. Peter Johann, a,current ... member of the Company,s,audit committee. The appointment fills ...
... 15 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... solutions, today declared a,dividend of $4.77 per share on ... dividend will be paid in shares of Series B,stock ... of (a) $4.77 divided by,(b) 97% of the average ...
Cached Biology Technology:Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... States stem from bat bites, far more people are treated ... most often reported rabid mammal. Controlling the spread of rabies ... where new outbreaks might occur and how the virus might ... journal PLoS Biology, Real and colleagues apply a mathematical model ...
... isn't very clear, especially when it comes to the vaccine ... end if you want to understand what the vaccine is ... 16, 2005 -- The European Vaccine Effort against HIV/AIDS today ... vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV ...
... Environmental Microbiology reveals that indigenous microbiota of the ... oil. Scientists from the Estación Experimental del Zaidín ... in situ crude oil degradation after the Prestige ... spill, hydrocarbons are subjected to physicochemical processes such ...
Cached Biology News:Rabies spread speeds up 2'EuroVacc 02' HIV Vaccine Trial Begins 2'EuroVacc 02' HIV Vaccine Trial Begins 3A hope for oil spill bioremediation 2
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biotin anti-human CD164...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
Biology Products: